Quoin Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell QNRX and other ETFs, options, and stocks.

About QNRX

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. 

CEO
Michael Myers
CEOMichael Myers
Employees
4
Employees4
Headquarters
Ashburn, Virginia
HeadquartersAshburn, Virginia
Founded
1986
Founded1986
Employees
4
Employees4

QNRX Key Statistics

Market cap
14.62M
Market cap14.62M
Price-Earnings ratio
-0.49
Price-Earnings ratio-0.49
Dividend yield
Dividend yield
Average volume
3.28M
Average volume3.28M
High today
$7.70
High today$7.70
Low today
$7.05
Low today$7.05
Open price
$7.33
Open price$7.33
Volume
178.27K
Volume178.27K
52 Week high
$41.80
52 Week high$41.80
52 Week low
$3.25
52 Week low$3.25

QNRX News

TipRanks 6h
Quoin Pharmaceuticals granted Rare Pediatric Disease Designation for QRX003

Quoin Pharmaceuticals (QNRX) announced that the FDA has granted Rare Pediatric Disease Designation for the company’s lead asset, QRX003, for the treatment of Pe...

Investing.com 6d
Tuesday’s insider buys and sells: Quoin Pharma executives lead purchases - Investing.com

...

Tuesday’s insider buys and sells: Quoin Pharma executives lead purchases - Investing.com

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.